Mabvax Therapeutics Hldgs Inc Com (NASDAQ:MBVX)

CAPS Rating: 1 out of 5

A biopharmaceutical company working to discover, develop and commercialize innovative small molecule drugs to treat diseases.

MBVX News and Commentary

Caps

How do you think MBVX will perform against the market?

Add Stock to CAPS Watchlist

All Players

57 Outperform
57 Underperform
 

All-Star Players

6 Outperform
28 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top MBVX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

PueoFool (< 20)
Submitted February 27, 2008

This is my vegas-style gamble for the week.

jed71 (99.86)
Submitted September 26, 2016

I normally would not bet against ZZLangerhans on a bio-tech but this one is being promoted. The promoter received $30K for his efforts in a two day promotion from 9/19 to 9/20. A snippet from the promotion is below:"Good morning traders, As we buckle… More

MBVX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about MBVX.

Recs

0
Member Avatar SmartAce (99.94) Submitted: 5/18/2017 11:02:06 AM : Underperform Start Price: $1.68 MBVX Score: +16.22

.Ten: Number of fingers children have. Twenty-six: Number of fingers children have when you try to put gloves on them.

Recs

5
Member Avatar jed71 (99.86) Submitted: 9/26/2016 11:44:45 AM : Underperform Start Price: $4.30 MBVX Score: +79.00

I normally would not bet against ZZLangerhans on a bio-tech but this one is being promoted. The promoter received $30K for his efforts in a two day promotion from 9/19 to 9/20. A snippet from the promotion is below:

"Good morning traders,

As we buckle in for fall expect to be hearing from us more often over the next three months. It is an exciting time for small cap’s with many turning their attention to this sector for near term profits as the Fed, election and oil cause concerns in the rest of the market.

We are going to start the week with an update on our last profile MabVax (NASDAQ: MBVX)

***UPDATE- news out 9am today
MabVax Therapeutics Reports on Interim Progress on Its Programs Including the Phase I Clinical Trial for Therapeutic Antibody Treatment of Pancreatic Cancer-

MBVX article from Sloan Kettering Cancer Center
New Cancer Imaging Approach Could Enable Better Detection of Pancreatic Tumors-

Excerpt from the article above-
“By comparing the middle and right panel, the researchers can confirm that 89Zr-DFO-5B1 is successfully going where it’s supposed to go in the body.

The drug was developed in the laboratory of MSK radiochemist Jason Lewis, in collaboration with the company MabVax Therapeutics Holdings.”

Laidlaw & Company recently issued a “Buy” rating with an $18 price target.

We are expecting an update from the company based on recent filings. If you missed our initial report’s, we have provided a copy below.

The Team"

And also, a snippet from the disclaimer at the very bottom of the letter:

"The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC has been compensated thirty thousand dollars’ cash via bank wire by third coast media llc for a two-day investor relations program of MBVX beginning on 9/07/16. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure. SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA."

Recs

4
Member Avatar YeahBuddy79 (96.72) Submitted: 5/5/2008 10:56:39 PM : Underperform Start Price: $64.80 MBVX Score: +176.41

Embarrassing at best. All the posts have already noted the deaths and that it kills people. As if that is not enough for you, this stock has a bad track record and it is falling faster then Cheney's approval rating. Not trying to get political (but it is true). Alright if you don’t know by now I really feel sorry for you. NEVER invest in the “cure for cancer” they will not find a cure they will find away to make you live with it. Don’t like that tuff break. The truth hurts. It is not like I want that don’t kill the informer. To be honest with you no company should be able to survive this. If it does I buy the CEOs a trophy for best killer that got away with it.

Leaderboard

Find the members with the highest scoring picks in MBVX.

Score Leader

zzlangerhans

zzlangerhans (99.77) Score: +279.38

Never write a biopharma off completely, especially when it comes to CAPS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
applefoot 58.69 9/13/2006 Underperform 3M $508.50 -99.72% +95.49% +195.21 0 Comment
studpicker 29.49 2/15/2008 Underperform NS $78.00 -98.15% +87.74% +185.89 0 Comment
foolishDAG 99.58 3/14/2007 Underperform NS $160.80 -99.10% +85.04% +184.15 0 Comment
ToePic < 20 2/25/2008 Underperform NS $78.60 -98.17% +85.56% +183.73 0 Comment
schwah4 28.98 4/3/2008 Underperform NS $78.60 -98.17% +82.70% +180.87 0 Comment
invstm100 73.38 6/9/2008 Underperform NS $57.90 -97.51% +82.60% +180.11 0 Comment
RagTimeCharley 87.53 3/21/2007 Underperform 5Y $165.30 -99.13% +80.74% +179.87 0 Comment
kesterdave < 20 12/20/2006 Underperform 3M $496.20 -99.71% +80.14% +179.85 0 Comment
AugustGray < 20 12/20/2006 Underperform NS $486.60 -99.70% +80.08% +179.79 0 Comment
Comatosis2007 < 20 12/28/2006 Underperform 1Y $132.00 -98.91% +79.87% +178.78 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackIcahn 91.83 9/30/2007 Outperform NS $87.30 -86.26% -51.07% -35.18 2/24/2009 @ $12.00 1 Comment
TrackJanney 87.52 12/27/2006 Underperform NS $141.00 +45.11% +3.62% -41.48 4/17/2007 @ $204.60 0 Comment
TrackStifel 94.32 12/27/2006 Underperform NS $141.00 +49.79% +3.77% -46.02 4/17/2007 @ $211.20 0 Comment
TrackLehmanBros < 20 11/15/2006 Underperform NS $540.00 -85.39% -3.14% +82.25 2/14/2008 @ $78.90 0 Comment

Featured Broker Partners